Abstract
Pentamidine isethionate is a trypanocidal drug used for the treatment of Pneumocystis carinii pneumonitis. Hematological complications have occasionally been reported and include anemia, leukopenia, and thrombocytopenia. We report here several qualitative abnormalities of in vitro platelet function and coagulation that have not been described previously. Platelets were exposed in vitro to concentrations of pentamidine isethionate ranging from 0.5 to 100 μg/ml of platelet-rich plasma. Clot retraction, platelet adhesiveness to glass beads, and platelet aggregation (adenosine 5′-diphosphate [ADP], thrombin, epinephrine, collagen, and ristocetin) were inhibited in a dose-dependent fashion. The addition of pentamidine isethionate after aggregation had been initiated with ADP reversed both primary and, to a lesser degree, secondary aggregation. Platelet factor 3 availability and serotonin uptake and release (using collagen as the releasing agent) were not inhibited. Serotonin release with 10−4 M ADP was slightly inhibited. Pentamidine isethionate prolonged the thrombin time of plasma at concentrations of 5 μg/ml and greater. The prothrombin time was prolonged at concentrations greater than 10 μg/ml of plasma. The inhibition of aggregation was reversed by washing and resuspension in plasma or by the addition of calcium or magnesium ions.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BORN G. V., CROSS M. J. THE AGGREGATION OF BLOOD PLATELETS. J Physiol. 1963 Aug;168:178–195. doi: 10.1113/jphysiol.1963.sp007185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Born G. V., Mills D. C. Potentiation of the inhibitory effect of adenosine on platelet aggregation by drugs that prevent its uptake. J Physiol. 1969 May;202(1):41P–42P. [PubMed] [Google Scholar]
- HARDISTY R. M., HUTTON R. A. THE KAOLIN CLOTTING TIME OF PLATELET-RICH PLASMA: A TEST OF PLATELET FACTOR-3 AVAILABILITY. Br J Haematol. 1965 May;11:258–268. doi: 10.1111/j.1365-2141.1965.tb06586.x. [DOI] [PubMed] [Google Scholar]
- IVADY G., PALDY L. Ein neues Behandlungsverfahren der interstitiellen plasmazelligen Pneumonie Frühgeborener mit fünfwertigem Stibium und aromatischen Diamidinen. Monatsschr Kinderheilkd. 1958 Jan;106(1):10–14. [PubMed] [Google Scholar]
- Levy M. A., Senior R. M., Sneider R. E. Severe thrombocytopenic purpura complicating pentamidine therapy for Pneumocystis carinii pneumonia. Cancer. 1974 Aug;34(2):441–443. doi: 10.1002/1097-0142(197408)34:2<441::aid-cncr2820340231>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
- Mills D. C., Smith J. B. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets. Biochem J. 1971 Jan;121(2):185–196. doi: 10.1042/bj1210185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Simone J. V., Vanderheiden J., Abildgaard C. F. A semiautomatic one-stage factor 8 assay with a commercially prepared standard. J Lab Clin Med. 1967 Apr;69(4):706–712. [PubMed] [Google Scholar]
- Waalkes T. P., Denham C., DeVita V. T. Pentamidine: clinical pharmacologic correlations in man and mice. Clin Pharmacol Ther. 1970 Jul-Aug;11(4):505–512. doi: 10.1002/cpt1970114505. [DOI] [PubMed] [Google Scholar]
- Western K. A., Perera D. R., Schultz M. G. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1970 Nov;73(5):695–702. doi: 10.7326/0003-4819-73-5-695. [DOI] [PubMed] [Google Scholar]